Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 22;17(1):368.
doi: 10.1186/s12913-017-2303-3.

Trends in healthcare expenditure in United States adults with chronic kidney disease: 2002-2011

Mukoso N Ozieh  1   2   3 , Kinfe G Bishu  2 , Clara E Dismuke  2   3 , Leonard E Egede  4   5
Affiliations

Trends in healthcare expenditure in United States adults with chronic kidney disease: 2002-2011

Mukoso N Ozieh et al. BMC Health Serv Res. .

Abstract

Background: This study examines trends in healthcare expenditure in adults with chronic kidney disease (CKD) and other kidney diseases (OKD) in the U.S. from 2002 to 2011.

Methods: One hundred and eighty-seven thousand, three hundred and fourty-one adults aged ≥18 from the Medical Expenditure Panel Survey (MEPS) Household Component were analyzed. CKD and OKD were based on ICD-9 or CCC codes. A novel two-part model was used to estimate the likelihood of any healthcare use and total expenditures. Covariates included individual demographics and comorbidities.

Results: Approximately 711 adults surveyed from 2002 to 2011 had CKD and 3693 had OKD. CKD was more likely among Non-Hispanic Blacks (NHB), Midwest and Western residents while OKD was more likely among Non-Hispanic Whites (NHW), Hispanics, married and Northeast residents. Both CKD and OKD were more likely in ≥45 years, males, widowed/divorced/single, ≤high school educated, publicly insured, Southern residents, poor and low income individuals. All comorbidities were more likely among people with CKD and OKD. Unadjusted analysis for mean expenditures for CKD and OKD vs. no kidney disease was $39,873 and $13,247 vs. $5411 for the pooled sample. After adjusting for covariates as well as time, individuals with CKD had $17,472 and OKD $5014 higher expenditures, while adjusted mean expenditures increased by $293 to $658 compared to the reference year group. Unadjusted yearly expenditures for CKD and OKD in the US population were approximately $24.6 and $48.1 billion, while adjusted expenditures were approximately $10.7 and $18.2 billion respectively.

Conclusion: CKD and OKD are significant cost-drivers and impose a profound economic burden to the US population.

Keywords: CKD; Healthcare expenditures; Medical expenditure panel survey.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Unadjusted total healthcare expenditures by kidney disease status, 2002–2011
Fig. 2
Fig. 2
Annual mean expenditures by kidney disease status for the US population, 2002–2011
See this image and copyright information in PMC

References

    1. Inker LA, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. Am J Kidney Dis. 2012;63(5):713–735. doi: 10.1053/j.ajkd.2014.01.416. - DOI - PubMed
    1. Centers for Disease Control and Prevention (CDC) National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014.
    1. Lozano R, Naghavi M, Foreman K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi: 10.1016/S0140-6736(12)61728-0. - DOI - PMC - PubMed
    1. Honeycutt A, Segel J, Zhuo X, Hoerger T, Imai K, Williams D. Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013;24:1478–1483. doi: 10.1681/ASN.2012040392. - DOI - PMC - PubMed
    1. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–272. doi: 10.1016/S0140-6736(13)60687-X. - DOI - PubMed